Grants to USA Research Entities, Agencies, IHEs, Nonprofits, and For-Profits for Migraine Treatment Research Projects

Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention

Agency

Foundation

GrantWatch ID#

209153

Funding Source

Patient-Centered Outcomes Research Institute (PCORI)

Geographic Focus

All USA

Important Dates

LOI Date: 05/31/23
Deadline: 08/29/23 5:00 PM ET

Grant Description

Grants to USA research entities, including agencies, IHEs, and nonprofit and for-profit organizations, for large-scale research trials to study migraine treatments. Applicants are required to submit a letter of intent prior to submitting a full application. Funding is intended for trials that will compare the effectiveness of pharmacologic and non-pharmacologic treatments for migraine prevention.

Through this PFA PCORI seeks to fund rigorous, large-scale, pragmatic trials that focus on newer pharmacologic agents, and/or evidence-based nonpharmacologic treatments for the prevention of migraine.

PCORI is particularly interested in studies that compare more recent pharmacologic options to standard prophylactic therapy or to each other. PCORI is also interested in studies that examine the comparative effectiveness of evidence-based nonpharmacologic options for migraine prevention as stand-alone therapy or as an adjunct to pharmacologic options. PCORI strongly encourages studies that are large enough to enable precise estimates of effect sizes and to support evaluation of potential differences in treatment effectiveness in patient subgroups.

For further program information, see https://www.pcori.org/sites/default/files/PCORI-2023-Cycle-2-Migraine-PFA.pdf#page=7.

Recipient

Additional Eligibility Criteria

In general, applications for the conduct of research and management of funding may be submitted by appropriate academic research, private sector research, or study-conducting entities. This may include, among others, agencies and instrumentalities of the Federal Government, nonprofit and for-profit research organizations, and colleges and universities.

Per PCORI’s authorizing statute, every applicant must demonstrate capability to comply with the following conditions:
- Abide by the transparency and conflicts of interest requirements that apply to PCORI with respect to the research managed or conducted under contract;
- Comply with the PCORI methodological standards adopted by the Board of Governors;
- Consult, as appropriate, with the expert advisory panels for clinical trials and rare disease;
- Deposit de-identified data from the original research into a PCORI-designated repository to facilitate data sharing, as appropriate;
- Have appropriate processes in place to manage data privacy and meet ethical standards for the research;
- Comply with the requirements of PCORI for making the information available to the public; and
- Comply with other terms and conditions determined necessary by PCORI to carry out the research project.

Potential applicants are strongly encouraged to review the standard research contract prior to application.

Ineligible

Individuals are not permitted to apply.

Categories of Nonresponsiveness: https://www.pcori.org/sites/default/files/PCORI-2023-Cycle-2-Migraine-PFA.pdf#page=13

Pre-Application Information

Key Dates:
- Online System Opens: May 2, 2023
- Applicant Town Hall: May 16, 2023; 12:00 - 1:00pm ET
- Letter of Intent Deadline: May 31, 2023; 5:00 pm ET
- Letter of Intent Status Notification: June 27, 2023
- Application Deadline: August 29, 2023; 5:00 pm ET
- Merit Review: November 2023
- Awards Announced: March 2024
- Earliest Start Date: July 2024

PCORI encourages all investigators interested in applying to request a conversation with a PCORI Program Officer via email prior to submitting a Letter of Intent.

Applying for funding through this PFA is a two-stage process. An LOI must be submitted, and an applicant must be invited to submit an application. Only applicants whose LOIs are deemed most responsive to this PFA will be invited to submit a full application.

Applicant FAQs: https://help.pcori.org/hc/en-us/categories/200010230-Applicant-Resources

Migraine Prevention FAQs: https://help.pcori.org/hc/en-us/categories/200010230-Applicant-Resources

View recorded Applicant Town Hall: https://www.pcori.org/events/2023/cycle-2-2023-comparative-effectiveness-novel-pharmacologic-and-evidence-based-nonpharmacologic-treatments-migraine-prevention-applicant-town-hall

Additional Funding Information

Estimated Total Program Funding:

$40,000,000

Estimated Size of Grant

Maximum Project Budget: $10 million (not inclusive of patient care cost coverage)

Term of Contract

The maximum allowable project period is five years (60 months).

Contact Information

Apply online: https://pcori.force.com/engagement/s/login/?ec=302&startURL=%2Fengagement%2Fs%2F

For programmatic inquiries, contact sciencequestions@pcori.org.

Patient-CenteredOutcomes Research Institute
1333 New Hampshire Ave NW, Suite 1200
Washington, DC 20036
Phone: 202-827-7700
Fax: 202-355-9558

Grants to USA Research Entities, Agencies, IHEs, Nonprofits, and For-Profits for Migraine Treatment Research Projects

Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention

We have foundations for

We have grants for

Cookies